trending Market Intelligence /marketintelligence/en/news-insights/trending/lgQuAtZH6ZiGpBArFoH36g2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

PhaseBio Pharmaceuticals appoints director


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

PhaseBio Pharmaceuticals appoints director

PhaseBio Pharmaceuticals Inc. appointed Edmund Harrigan to its board, effective Dec. 13.

Harrigan is also a board member of Bellicum Pharmaceuticals Inc., Karuna Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc. and Lyndra Therapeutics.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat orphan diseases.